Nintedanib in advanced NSCLC: management of adverse events.

IF 0.9 Q4 RESPIRATORY SYSTEM Lung Cancer Management Pub Date : 2016-04-01 Epub Date: 2015-11-03 DOI:10.2217/lmt.15.33
Liesbeth Lemmens
{"title":"Nintedanib in advanced NSCLC: management of adverse events.","authors":"Liesbeth Lemmens","doi":"10.2217/lmt.15.33","DOIUrl":null,"url":null,"abstract":"<p><p>Nintedanib plus docetaxel is approved in the EU for the treatment of patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy. Nintedanib in combination with docetaxel has a manageable safety profile in adenocarcinoma NSCLC patients. The most frequent adverse events (AEs) associated with nintedanib are gastrointestinal events and elevations in liver enzymes. Most AEs can be managed effectively with supportive treatment or a dose reduction and do not require permanent discontinuation. This article aims to provide practical guidance on management of AEs and how patients should be assessed for AEs prior to initiation and regularly monitored throughout treatment. Patients and their carers can play an important role in recognizing and managing AEs and should be given the relevant information, skills and confidence to achieve this.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 1","pages":"29-41"},"PeriodicalIF":0.9000,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt.15.33","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt.15.33","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/11/3 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 9

Abstract

Nintedanib plus docetaxel is approved in the EU for the treatment of patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy. Nintedanib in combination with docetaxel has a manageable safety profile in adenocarcinoma NSCLC patients. The most frequent adverse events (AEs) associated with nintedanib are gastrointestinal events and elevations in liver enzymes. Most AEs can be managed effectively with supportive treatment or a dose reduction and do not require permanent discontinuation. This article aims to provide practical guidance on management of AEs and how patients should be assessed for AEs prior to initiation and regularly monitored throughout treatment. Patients and their carers can play an important role in recognizing and managing AEs and should be given the relevant information, skills and confidence to achieve this.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Nintedanib治疗晚期NSCLC:不良事件的处理。
欧盟批准宁替达尼联合多西他赛治疗一线化疗后局部晚期、转移性或局部复发的腺癌组织学NSCLC患者。宁替达尼联合多西他赛治疗腺癌NSCLC患者具有可控的安全性。与宁替达尼相关的最常见不良事件(AE)是胃肠道事件和肝酶升高。大多数AE可以通过支持性治疗或减少剂量有效控制,不需要永久停药。本文旨在为AE的管理以及如何在开始治疗前对患者进行AE评估和在整个治疗过程中定期监测提供实用指导。患者及其护理人员可以在识别和管理AE方面发挥重要作用,并应获得实现这一目标的相关信息、技能和信心。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lung Cancer Management
Lung Cancer Management RESPIRATORY SYSTEM-
CiteScore
2.30
自引率
0.00%
发文量
1
期刊最新文献
Increased sympathetic nervous system impairs prognosis in lung cancer patients: a scoping review of clinical studies. Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC Bilateral synchronous multiple lung cancer: an emerging problem A retrospective study of ensartinib-treated ALK-positive locally advanced or metastatic NSCLC patients in China Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1